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Abstract
The goal of this chapter is to identify medications frequently utilized for sedation and
analgesia in Extracorporeal Membrane Oxygenation (ECMO) patients. In addition to
describing basic pharmacologic principles of these medications, we discuss their benefits
and disadvantages and explain the effects the ECMO circuitry will have on pharmacoki‐
netics of each drug. We also discuss need for various depths of sedation and the utility of
neuromuscular blocking agents. Emerging techniques for achieving appropriate sedation
will be identified. An explosion of literature in recent years has led to Intensive Care Unit
(ICU) delirium increasingly being recognized as an indicator of poor outcomes in the
general ICU population. We discuss strategies to manage this complex and multifactori‐
al issues, and how they can be applied to our particular subpopulation of ECMO patients.
Keywords: sedation, analgesia, agitation, delirium, neuromuscular blocking agents,
ECMO sequestration
1. Introduction
The basic principles of initiation and titration of sedatives and analgesics in the critically ill
apply to those on Extracorporeal Membrane Oxygenation (ECMO). There are, however, some
unique characteristics that pertain to the patient as well as the ECMO device itself that may
help guide the intensivist in this particular subset. We will describe the basic pharmacologic
principles of commonly used medications for providing sedation and analgesia and nonphar‐
macologic interventions. Emerging techniques for achieving appropriate sedation will be
identified that include ECMO in the awake patient.
The ECMO circuitry has its own unique effects on the pharmacokinetics of each drug. We will
also discuss the need for various depths of sedation and the utility of neuromuscular blocking
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
agents. This chapter also includes a discussion of monitoring and identifying the emerging
techniques for management of sedation, analgesia, and delirium that include ECMO in the
awake patients.
The reader should be able to identify the most commonly used analgosedation practices in
ECMO patients after reading this chapter as well as the emerging techniques. They should
understand the effect of the ECMO circuitry on pharmacokinetics of each drug described. We
also hope to increase the understanding of the complex issue of Intensive Care Unit (ICU)
delirium. The authors hope the readers will use the information to develop a systematic
approach for delivering and titrating targeted analgosedation as well as for identifying and
managing delirium in the critically ill ECMO patient.
2. Sedation and analgesia
The American College of Critical Care Medicine task force recently revised its clinical practice
guidelines for the management of pain, agitation, and delirium in critically ill adult patients
[1]. These guidelines recognize that pain is common in Intensive Care Unit (ICU) patients and
may lead to both acute and long-term sequelae. In the acute setting, pain increases the
proinflammatory balance of cytokines and may contribute to tissue hypoperfusion due to
arteriolar vasoconstriction [2,3]. Opiates decrease this stress response and decrease tissue
metabolic oxygen consumption [2]. Later, acute pain may lead to PTSD and Chronic Pain in
patients who survive their critical illness [4,5]. Sedatives such as benzodiazepines may be used
to decrease the stress response; however, they may have negative consequences that could
worsen outcomes in ICU patients [1]. The 2013 guidelines thus advocate for pain assessment
in ICU patients and an “analgesia-first” approach to sedation [1]. For patients undergoing
ECMO, many considerations are similar to those encountered in other critically ill populations;
however, certain factors will require additional consideration in this vulnerable group.
Ultimately, the choice of medication for sedation and analgesia in a patient on ECMO will rely
on multiple pharmacokinetic and pharmacodynamics considerations, clinical circumstances,
patient’s variables, and the goals of the team managing the patient [6].
Although intravenous opioids have been a mainstay of ICU analgesia for many years, much
of the pharmacokinetic data comes from single-dose studies in healthy volunteers [7,8]. ECMO
further complicates the situation by altering the pharmacokinetics of analgesics and sedatives
[9,10]. The depth and duration of sedation as well as the titratability of the medication(s)
selected must be considered. Often the level of sedation tolerated will depend on the patient’s
stability and sedation goals may vary considerably over time. This is especially true during
the initial period after initiation of ECMO. At this stage, greater levels of sedation and
sometimes chemical paralysis may be required. At the same time, the patient is frequently still
in a state of hemodynamic or metabolic shock. Patients with an open chest due to central
cannulation and those who require multiple painful procedures will require a greater degree
of sedation to decrease movement and the consequent risk of cannula dislodgement. Medica‐
tion interactions with the ECMO circuit itself must also be taken into account. Circuit seques‐
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tration of highly lipophilic medications will decrease their bioavailability. This issue will be
discussed in more detail in a later part of this chapter. Renal and hepatic functions are often
impaired in patients requiring ECMO [11]; thus, the half-life of many medications can be
prolonged; metabolites and compounding agents such as propylene glycol may accumulate
leading to unwanted side-effects.
Route of administration is another concern with critically ill patients on ECMO. Enteral
administration is cheaper and decreases reliance on parenteral access but may result in erratic
and unpredictable absorption [6]. Submucosal and IM administration is generally unreliable
in patients suffering from shock [8]. The 2013 Clinical Practice Guidelines from the Society of
Critical Care Medicine consequently recommend intravenous opioids as the first-line drug
class of choice to treat nonneuropathic pain in critically ill patients [1]. Intravenous adminis‐
tration provides faster onset, higher bioavailability, and rapid titratability [8]. This proves
advantageous when administering medication prior to an invasive procedure or when
following a sedation protocol. As the patient progresses in their course, lesser levels of sedation
and analgesia may be required and minimal analgesia and sedation may be necessary [12]. At
this point, continuous infusions may be discontinued and intermittent dosing of analgesics
may prove sufficient.
All the available IV opioids can be titrated to achieve equally effective levels of analgesia [1];
thus the main difference between opiates comes down to cost, pharmacokinetic properties,
and pharmacodynamic distinctions [6]. Opioids with agonist-antagonist properties should be
avoided in critically ill patients in general due to decreased analgesic efficacy and the potential
for triggering withdrawal in opiate dependent patients [6]. Meperidine is an undesirable choice
because of potential drug interactions with serotonergic and dopaminergic agents, vagolytic
side effects and the buildup of normeperidine, a metabolite which lowers the seizure threshold
[8]. Fentanyl, a synthetic opioid with a rapid onset and short distribution half-life, is one of the
most commonly used opioids in the ICU [13]; however, because fentanyl and its derivatives,
sufentanil, alfentanil, and remifentanil, are highly lipophilic, they are extensively consumed
by the ECMO circuit [10]. It has been demonstrated that within hours of administration, nearly
the entire dose of fentanyl is lost in an ex vivo ECMO circuit primed with blood [14,15]. With
such rapid absorption rates, exceedingly high doses of fentanyl would be required to maintain
the desired level of analgesia. Furthermore, a patient previously exposed to high doses of
opiates may experience withdrawal if placed on ECMO while already receiving fentanyl
analgesia. Fentanyl may thus best play the role of a rapid onset analgesic used for brief but
painful procedures.
From a pharmacokinetic standpoint morphine may be the preferred analgesic during ECMO.
Because it is hydrophilic, it shows little absorption into the ECMO circuit [14,15]. Morphine
was in fact considered the “preferred analgesic agent for critically ill patients” by the older
1995 guidelines for analgesia and sedation published by the Society of Critical Care Medicine
[16]. Some of morphine’s attributes however make it less desirable for use in the critically ill
population. Histamine release from morphine may contribute to bronchospasm and hypoten‐
sion [6]. In renal failure, accumulation of the active metabolite morphine-6-glucuronide may
lead to prolonged sedation. Hydromorphone, a semisynthetic opiate, may thus prove a more
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suitable option for IV analgesia in patients on ECMO. Although there is no specific study of
hydromorphone’s pharmacokinetics in an ECMO circuit, the drug’s hydrophilic nature should
keep sequestration at acceptable levels. There is no histamine release associated with large
doses of hydromorphone, and although the parent drug may accumulate in renal and hepatic
impairment, there are no active metabolites. The half-life of hydromorphone is 2–3 h, allowing
for either intermittent bolus dosing or a continuous infusion to maintain the desired level of
analgesia. Oxycodone, another semisynthetic opioid, may be given enterally for patients who
are expected to have adequate absorption from their gastrointestinal tract. It is metabolized
by the cytochrome P450 system, thus the dose should be reduced in hepatic dysfunction. Peak
effect is reached after approximately 30 minutes to an hour and the duration of its effect is
approximately 3–6 h. Oxycodone is relatively hydrophilic and so should not significantly bind
to the ECMO circuit.
Analgesic adjuncts such as intravenous (IV) acetaminophen, gabapentin, ketamine, and
dexmedetomidine may be used to decrease reliance on opioid analgesics and minimize their
side effects. Unfortunately, many of these medications have only been studied on a limited
basis in the ICU population, and data for patients receiving ECMO is remarkably limited. IV
acetaminophen has been approved by the US Food and Drug Administration (FDA) for use
along with opioids for pain management after major and cardiac surgery [17,18]. However, it
has not been studied for extended periods of time or in a population with a high incidence of
organ failure such as ECMO patients [19]. Additionally, the benefits of acetaminophen may
not be as apparent or relevant in a population that requires long-term ICU level care. Neuro‐
pathic pain in settings such as burns, neuralgia, and neuropathy tends to be poorly treated by
opioids [1]; however, it may respond to medications such as gabapentin and pregabalin that
target calcium channels in the central nervous system [6,20]. If patients have been started on
these medications due to pre-existing conditions, continuation of the therapy is prudent to
avoid withdrawal. Unfortunately, pharmacokinetics can be complicated by unpredictable
absorption from the GI tract, renal dysfunction, renal replacement therapy, and uncertain
interactions with the ECMO circuit.
Since ECMO is frequently complicated by hemodynamic instability and rapidly escalating
requirements for sedation and analgesia [9], ketamine infusions have been used to optimize
patient comfort without increasing the depth of sedation or contributing to hypotension.
Ketamine is an NMDA antagonist that has been shown to augment opiate analgesia without
decreasing sympathetic tone [21]. Limited data exists on long-term ketamine use in critically
ill patients; however, some trials have shown decreased opiate usage, improved gastrointes‐
tinal motility, and decreased vasopressor requirements in patients treated with ketamine [22].
Similarly, a retrospective review of ketamine in 26 ECMO patients treated at a single center
demonstrated a decrease in vasopressor requirements and a decrease in sedation requirements
while maintaining the same level of sedation [23]. The doses of ketamine used in the ECMO
trial (50–150 mg/H) were substantially higher than those described for analgesia in other
studies. Since ketamine is lipophilic, this may be attributable to circuit sequestration of
ketamine. A possible concern with ketamine analgesia in patients, who have cardiogenic shock,
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is that the increase in blood pressure may come at the expense of a decrease in cardiac output
and an increase in systemic and pulmonary vascular resistance [24].
When an analgesia-based regimen is insufficient to provide adequate patient comfort, or a
greater depth of sedation is required due to clinical circumstances, a sedative may be initiated.
Just as opiates have been the mainstay of analgesia in the ICU, benzodiazepines have tradi‐
tionally been used for sedation in critically ill patients. Benzodiazepines activate  -aminobutyric
acid A receptors in the central nervous system leading to anxiolysis, amnesia, sedation, and
an increase in the seizure threshold [8]. Recent evidence however has identified these agents
as a leading, modifiable cause of delirium in hospitalized patients and implicated them in
prolonging the duration of mechanical ventilation and ICU stays [25–27]. Other agents such
as propofol and dexmedetomidine have shown superiority in comparison to benzodiazepines
by reducing ICU stays and duration of delirium [26–28].
Of the benzodiazepines, midazolam is frequently used as an infusion for short to intermediate
duration sedation of ICU patients [8]. It is water soluble, has a rapid onset of action, and a
relatively shorter half-life of 2–5 h. However, with prolonged infusion, midazolam and its
active metabolite 1-hydroxymidazolam glucuronide may accumulate, contributing to pro‐
longed sedation and respiratory depression. Liver and renal failure may both prolong this
effect. Lorazepam is metabolized by glucuronidation in the liver to an inactive metabolite and
is thus less affected by renal and hepatic dysfunction. Since it has a longer half-life of 10–20 h,
it may be given as an infusion or bolused on an as needed basis. Midazolam is highly lipophilic
and is to a large extent absorbed by the ECMO circuit. In one study 50% of midazolam remained
available after 30 min of in vitro ECMO circulation, and only 13% was detected after 24 h [29].
On the other hand, another study evaluated lorazepam and showed that 70% of lorazepam
remained at 24 h [61]. Since lorazepam is somewhat less lipophilic, a lesser degree of seques‐
tration would be anticipated.
Of the nonbenzodiazepine sedatives, propofol is extensively absorbed by the ECMO circuit
[30]. This property and its tendency to cause hypotension would make propofol a less desirable
agent for the sedation of patients on ECMO. Dexmedetomidine, a selective alpha-2 receptor
agonist, with sedative and analgesic properties, has demonstrated substantial advantages over
benzodiazepines in the care of critically ill patients. Patients sedated with dexmedetomidine
are more easily aroused, have a reduced incidence of delirium, decreased sympathetic tone,
and less respiratory depression [1,28]. A recent study showed that addition of dexmedetomi‐
dine to standard care of agitated, mechanically ventilated patients resulted in more rapid
resolution of delirium and more ventilator free days [31]. Dexmedetomidine may not be
appropriate in patients requiring a deep level of sedation or those with hypotension or
bradycardia [6]. Dosage adjustments will likely be required for patients on ECMO due to
significant interactions with the PVC tubing of the circuit [32].
Monitoring levels of sedation and analgesia is crucial in decreasing the likelihood of undesired
outcomes [1]. Chanques et al. demonstrated that a protocol for systematically assessing and
treating pain and agitation in critically ill patients not only decreased pain and agitation but
also decreased the duration of mechanical ventilation and the incidence of nosocomial
infections in a mixed medical-surgical population [33]. Although a patient’s self-assessment
Sedation, Analgesia Delirium in the ECMO Patient
http://dx.doi.org/10.5772/64249
291
of pain is considered the “gold standard” for pain assessment, this is frequently difficult to
obtain in the ICU setting. Hemodynamic indicators of pain are not validated or reliable [1].
Behavioral scales have been developed as an objective tool for measuring pain in patients
unable to communicate. Two scales in particular, the Behavioral Pain Scale and the Critical
Care Pain Observation Tool have been found to be both reliable and valid in patients who are
unable to report pain but have intact motor function [34]. Although further validation and
study is warranted, implementation of these scales has been shown to be feasible and to lead
to improved pain management and clinical outcomes [33,35,36]. Whether such protocols of
pain assessment and titration would improve outcomes in ECMO patients remains to be seen.
With regard to sedation, the Richmond Agitation-Sedation Scale (RASS) and the Sedation-
Agitation Scale (SAS) are considered the most valid and reliable sedation assessment tools for
measuring depth of sedation. They demonstrate high inter-rater reliability as well as conver‐
gent and discriminant validation in a relatively high number of subjects [1]. The RASS
additionally provides a goal for the titration of sedation. In patients who are chemically
paralyzed, as ECMO patients may be immediately after cannulation, one of several objective
sedation monitors, such as the bispectral index (BIS), Narcotrend Index, Patients State Index
or state entropy, should be used [1]. Electroencephalogram monitoring should be used in
patients suspected of having nonconvulsive seizures.
3. Neuromuscular blockade and ECMO/ARDS
Neuromuscular blocking agents (NMBAs) have been controversial with regard to their efficacy
in treating acute respiratory distress syndrome (ARDS) (we will not discuss the use of NMBAs
for the initial intubation of the patient). Due to lack of evidence on a large scale, no clear
recommendations exist regarding the use of NMBAs in ARDS. Early work suggested that
anesthesia and paralysis cause a ventilation/perfusion mismatch and impair gas exchange [37].
The traditional view on NMBA use in the critical care setting is largely negative, with a number
of potential complications associated with this therapeutic modality [38,39]. However, other
work over the past 12 years has indicated that use of NMBAs in acute respiratory distress
syndrome (ARDS) has been shown to improve oxygenation and decrease mortality in most
hypoxemic patients [40]. What is applicable in ARDS is also applicable in ECMO because
ECMO is just a further device extension beyond ventilators and high-frequency oscillators
[41,42].
Gannier et al. asserted that the hypoxemia in ARDS reaches its worst levels in the first 48 h. In
a study of 56 patients with ARDS, improved oxygenation was seen in patients randomized to
NMBAs in the first 48 h while receiving volume assist control with a tidal volume of 6–
8 ml/kg [43]. Another similar study reported that early NMBA use may contribute to modu‐
lation of the pro-inflammatory response [44]. Additionally, a third study of 340 patients where
cis-atracurium was administered in the first 48 h of development of ARDS found that the
NMBAs improved the adjusted 90-day survival and increased time off of the ventilator without
increasing muscle weakness [45].
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Two recent meta-analyses based on randomized control trials analyzed the use of NMBAs in
ARDS. Neto et al. performed a systematic review of the literature and meta-analysis of studies
conducted between 1966 and 2012, and the three abovementioned studies were the only
acceptable, high-quality trials performed [46]. The authors concluded, based on these three
studies, that that the use of NMBAs in the early stages of ARDS leads to an improved outcome.
Alhazzani et al., in a second meta-analysis, demonstrated a decreased mortality rate at 28 days
among those receiving NMBAs in early ARDS [47]. They stated that nine patients need to be
treated to save one life. They also found that there was a reduced risk of barotrauma and an
increased number of days without mechanical ventilation during the first four weeks in those
receiving NMBAs. Furthermore, they showed that the PaO2:FiO2 ratio was improved at one,
two, and three days.
Physicians must be aware of the potentially important pathophysiological events that can
occur with the use of NMBAs in hypoxemic patients [40]. These include increases in thoraco‐
pulmonary compliance, functional residual capacity, perfusion of ventilated spaces, and
recruitment of portions of the lung that have little compliance. There can be decreases in
pulmonary shunt, muscular O2 consumption, overdistention of high-compliance areas,
derecruitment, end-expiratory collapse, asynchronous patient-ventilator dynamics, barotrau‐
ma, volutrauma, biotrauma, and atelectrauma. The debate continues as to the best ventilation
practices/strategy in ARDS. The problem with NMBAs is that they seem to eliminate the
opportunity for the use of spontaneous modes [40].
Additionally, every practicing intensivist must be aware of ICU-acquired weakness (ICUAW),
a polyneuropathy and/or myopathy, that occur in 34–60% of the patients with ARDS [48–50].
It was associated with independent risk factors such as organ dysfunction, female gender,
length of time on a ventilator, and corticosteroid administration [51], and there is some
evidence it is related to hypothermia, hyperglycemia, ICU length of stay, low albumin, and
vasopressors [52–54]. While NMBAs have historically been associated with ICUAW, recent
evidence contradicts this view, at least with nonsteroidal NMBAs [40].
It is of great importance to use a nerve stimulator for the monitoring of neuromuscular
blockade [55]. If the dose of NMBAs is limited, there may be a decrease in the subsequent risks
of ICUAW and complications from residual neuromuscular blockade [56]. Peripheral nerve
stimulator use is mandatory in order to facilitate appropriate titration of NMBAs. Train of four
(TOF) monitoring is the primary method for assessment of NMBA and generally involves the
use of supramaximal electrical impulses every 0.5 s applied to the ulnar, facial, or posterial
tibial nerve with a resultant identifiable pattern or response [55]. Instruction in TOF monitoring
is beyond the scope of this chapter.
Hraiech et al. make the observation that based on the available evidence provided by random‐
ized control trials, NMBAs can be integrated safely into the concept of protective ventilation
[40]. The use of NMBAs should be confined to the acute phase of ARDS. Spontaneous breathing
must be encouraged when the severe phase has passed and in those with mild and moderate
ARDS from the outset. Finally, never forget to sedate a patient in which a NMBA is used. In
some countries, such as the USA, this can be a cause of legal action or discipline [57]. While
the above suppositions related to NMBAs were not directly related to ECMO, the difficulty in
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oxygenating an ECMO patient should at least lead to the consideration of pharmacologic
paralysis.
4. Drug sequestration in ECMO
Drug therapy while a patient is on ECMO may be affected by multiple pharmacokinetic
alterations, including volume of distribution and protein binding. One of the reasons a
patient’s volume of distribution may be increased is due to sequestration of drug within the
ECMO circuit. Sequestration of drugs into the ECMO circuit is a well-known phenomenon
with certain drug properties predicting which medications may bind to the ECMO circuit [15].
Medications that are considered lipophilic, such as propofol, will have a high octanol/water
partition coefficient (log P) and will be soluble in organic materials such as PVC tubing [15].
Conversely, medications that are considered hydrophilic may be unaffected by the ECMO
circuit. In an ex vivo study performed by Lemaitre and colleagues, the concentration of
propofol decreased to 11% of expected values after 24 h in a closed ECMO circuit [30], while
concentrations of vancomycin, a relatively hydrophilic drug, remained unchanged.
In addition to lipophilicity, the degree of a drug’s protein binding may affect sequestration in
the ECMO circuit. Shekar and colleagues performed an ex vivo study and determined that
drugs with significantly reduced concentrations at 24 h were either highly protein bound
(>80%), highly lipophilic (log P > 2.3), or both [60]. For medications with the similar lipophi‐
licity, the degree of drug recovery was based on protein binding. Both ciprofloxacin and
thiopentone have similar lipophilicity (log P 2.3; however, greater reductions were seen in the
drug with higher protein binding, thiopentone (88%), compared with ciprofloxacin (4%). This
held true when comparing two hydrophilic drugs vancomycin and ceftriaxone. Circuit drug
recovery at 24 h was higher for vancomycin (91%) compared with ceftriaxone (80%), which is
more highly protein bound. It is unclear of why highly protein bound drugs bind to the ECMO
circuit. It is postulated that proteins in the priming solution or in the patient’s blood bind to
the circuit and then the drug in turn binds to the protein sequestered in the circuit. Drugs that
are both lipophilic and highly protein bound may be more prone to sequestration in the circuit.
As an example, fentanyl a highly protein bound and lipophilic drug has been studied in ECMO
with extreme reductions in concentrations (97%) at 24 h [14]. However, it is still unclear if the
presence of both properties results in additive binding within the circuit.
In addition to considering drug properties to predict sequestration, it is imperative to evaluate
the ECMO circuit components and their materials. Wildschut and colleagues showed signifi‐
cant differences in drug recovery for both fentanyl and midazolam in neonatal centrifugal
pumps compared to neonatal roller pumps [15]. The neonatal centrifugal pumps had nearly
one hundred fold increases in drug recovery for fentanyl and midazolam compared with the
roller pumps, which may be due to the fact that roller pumps require more PVC tubing,
potentially increasing the amount of drug-binding sites. The PVC tubing and membrane
oxygenators used in ECMO have both been shown to sequester drug within the ECMO circuit;
however, the PVC tubing is presumed to be responsible for the removal of a vast majority of
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the drugs [61,62]. It is unclear if saturation of drug-binding sites on the PVC tubing occurs, as
studies comparing drug recovery in new and used ECMO circuits show variable results
[15,32,61]. The limitation of all of these studies is the short duration (<48 h) of drug exposure
to the ECMO circuit. As ECMO has been used clinically for much longer periods of time, it is
unclear if or when saturation of the ECMO circuit occurs and how this may impact drug
therapy.
Once a patient is placed on the ECMO, drug sequestration is just one of the factors that can
cause pharmacokinetic changes. Data for sequestration of drugs in the ECMO circuits are
limited, and it is important to understand the majority of the data is derived from ex vivo
experiments. When caring for a patient on the ECMO, it is imperative to consider the drug
properties, type, and duration of ECMO, and patient’s factors that influence drug dosing in
order to prevent harm and/or therapeutic failure.
5. Delirium
Often used interchangeably with the term “acute brain dysfunction,” delirium has consistently
been shown to be an independent predictor of poor short-term outcomes in the critically ill.
This includes increased mortality in mechanically ventilated patients as well as prolonged
hospital and ICU stays [63,64]. There is now increasing evidence of delirium’s ill effects in the
long term as well. Long-term cognitive impairment has been linked to the development and
duration of delirium in the ICU setting [65].
Delirium is defined as a disturbance in attention and awareness which is an acute change from
baseline. Typically, it develops over a short period of time (over hours to days) and fluctuates
throughout the course of the day. Patients often present with additional disturbances in
cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception)
[66,67].
There are three subtypes of delirium that are based on the patient’s level of alertness: “hyper‐
active,” “hypoactive,” and “mixed.” Often hypoactive delirium goes unrecognized and has
been linked to poorer outcomes [68].
Patients on the ECMO are particularly vulnerable to the development of delirium given their
severity of illness and comorbidities. Four independent risk factors for transition to delirium
have been identified: pre-existing dementia, history of hypertension, and/or alcoholism, and
a high severity of illness at admission [6]. However, there are many other factors that have
been associated with this form of acute brain dysfunction—these can be further stratified based
on (1) illness (2) patient’s factors, and (3) environmental or iatrogenic factors [69] (Table 1).
Care of the delirious patient in the ICU should focus on a three-step approach of monitoring,
preventing, and treating delirium. At this time, there is limited data on delirium in the ECMO
patients. Further research is essential in determining an evidence-based algorithm in the
ECMO patient as there are many unique patient- and equipment-related factors specific to
these patients that need to be investigated. The Confusion Assessment Method for the
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Intensive Care Unit (CAM-ICU) is the most frequently applied screening and monitoring tool
in the ICU setting (Figure 1) [70]. Proper assessment will guide further interventions.
Figure 1. Confusion assessment method for the ICU (CAM-ICU) Flow sheet.
Illness Patient’s factors Environmental/iatrogenic factors
Cardiovascular instability Cognitive impairment, pre-
existing dementia, and
depression
Diagnostic procedures and therapeutic
interventions
Acid base disorders Age > 65 Use of restraints
Electrolyte abnormalities Sensory deprivation: need for hearing aids
and glasses
Sepsis Sleep deprivation
Respiratory distress
Acute CNS abnormalities
http://www.mc.vanderbilt.edu/icudelirium/
terminology.html
Table 1. Factors that have been associated with delirium.
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Primary prevention should focus on decreasing the risk factors and minimizing iatrogenic
causes known to increase the likelihood of transition to delirium. Management for both
prevention and treatment can be further subcategorized into nonpharmacologic and pharma‐
cologic interventions. These include minimizing loud noises and interruptions, a nonpharma‐
cologic sleep protocol, stimulation during the day, and frequent reorientation to person, place,
and time. Pharmacologic prevention of delirium has not been shown to decrease the likelihood
of its occurrence [6]. The authors believe this practice may actually lead to over sedation and
increase the likelihood of transition to delirium and do not recommend this approach based
on existing evidence at this time. Daily assessment of analgesia and sedation requirements and
deliberate choices in agents are an important part of the management (Figure 2).
Figure 2. 'Wake up and breathe' protocol.
Benzodiazepines have been proven in multiple ICU settings to increase the likelihood of
transition to delirium [71, 72]. Traditionally, they have been used for deep sedation in the
ECMO patients because of their relative preservation of hemodynamic stability and unique
pharmacologic property of lorazepam that would ensure adequate plasma concentrations in
patients on the ECMO. In the future, the use of deep sedation with medications that remain in
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the system long after titrating off may lead to this practice being called into question. Deep
sedation may be provided with multiple other sedatives that were discussed in the section
regarding sedation and analgesia.
As further evidence emerges, prevention and treatment of delirium in the ECMO patient will
become more standardized. Early mobilization and liberation from mechanical ventilation
should be included in goals for prevention and management of delirium in the ECMO patient.
There is compelling evidence that protocol-based treatment with these goals in mind can
improve clinical outcomes in the general ICU population [73].
In keeping with the goal of early liberation of mechanical ventilation, many centers are
exploring strategies for the use of ECMO in the awake patient. This may decrease the morbidity
and mortality associated with mechanical ventilation, deep sedation, and immobility that have
traditionally accompanied the use of ECMO. Additionally, it is possible for patients to breathe
spontaneously, which might prevent respiratory muscle atrophy. While this has been best
documented in the pediatric population and adult VV-ECMO patients being bridged to lung
transplantation, this could also be utilized in the VA-ECMO patient. In such a case, close
monitoring would be essential to ensure that the patient’s breathing pattern and neurologic
status are not compromising the patient’s hemodynamics and respiratory status [74–76].
6. Conclusion
Increasingly, complications related to sedation, analgesia, and delirium are being recognized
as factors that may play a role in morbidity of the critically patient. The decision to initiate
medications for sedation, pain control, or agitation should be made by a clinician with intimate
knowledge of the most commonly used agents. The use of deep sedation, light sedation, or
minimal sedation should be decided upon based on the clinical picture specific to each
individual patient on VA or VV ECMO. Pain must be accurately assessed in patients who may
or may not be able to verbally express pain scores and titrated to response. The initiation of
medications for agitation or anxiety must be decided upon with careful consideration in this
critically ill population and the need for these medications should be reviewed on a daily basis.
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